Chen Chen

Cooley advised Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein-coupled receptor (GPCR)-targeted radiopharmaceuticals to treat a broad range of solid tumors, on the formation of a strategic agreement with Eli Lilly to take forward Radionetics’ proprietary GPCR-targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million up-front cash payment. Additionally, Lilly obtained the exclusive right to acquire Radionetics for $1 billion upon conclusion of an exercise period.

Cooley advised ARCH Venture Partners, which co-led a $1 billion Series A funding round in Xaira Therapeutics. Partners Colleen Badgley, Danielle Naftulin and Dave Peinsipp led the Cooley team advising ARCH, a venture capital firm catalyzing discoveries that prevent, detect and cure disease.

Cooley advised MediLink Therapeutics, a clinical-stage biotech company focused on developing globally competitive conjugated drugs, on its strategic research collaboration and worldwide license agreement with BioNTech.

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche.